Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

INSANE: Teva pharma boosts outlook for key innovative drugs austedo ajovy uzedy | Rare Historical Photos

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.

The company reported total revenue of $4.20 billion, falling short of analysts’ expectations of $4.29 billion, according to Benzinga Pro. This marks a flat year-over-year result in U.S. dollars, with a slight decline of 1% in local currency terms.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.